融券方面，当日融券卖出0.17万股，净买入0.78万股。 来源：金融界 7月31日，沪深两融数据显示，通策医疗获融资买入额1.18亿元，居两市第174位，当日融资偿还额1.15 亿元，净买入240.43万元。 最近三个交易日，29日-31日，通策医疗分别获融资买入1.42亿元、1.35亿元、1.18亿元。 ...

融券方面，当日融券卖出0.03万股，净卖出0.02万股。 来源：金融界 7月31日，沪深两融数据显示，三星医疗获融资买入额0.68亿元，居两市第323位，当日融资偿还额0.90 亿元，净卖出2236.06万元。 最近三个交易日，29日-31日，三星医疗分别获融资买入0.52亿元、0.29亿元、0.68亿元。 ...

证券代码：600227 证券简称：赤天化 编号：2025-051 贵州赤天化股份有限公司关于提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称及是否为上市公司关联人：被担保人贵州大秦肿瘤医院有限公司（以下简称"大秦医 院"）和贵州赤天化桐梓化工有限公司（以下简称"桐梓化工"）系公司的全资子公司。 ●本次担保金额及已实际为其提供的担保余额：①2025年7月，公司对大秦医院增加担保金额为2,446万 元，截止至2025年7月31日，公司累计为大秦医院提供担保余额为63,294.44万元；②2025年7月，公司对 桐梓化工增加担保金额为7,000万元，截止至2025年7月31日，公司累计为桐梓化工提供担保余额为 52,080万元；2025年7月，公司提供担保的子公司归还借款金额11,100万元，截止至2025年7月31日，公 司及公司控股子公司对外担保总额为115,374.44万元，对外担保均为公司为报表合并范围内的子公司提 供的担保。 ●本次担保是否有反担保：否 ●对外担保逾期的累计 ...

The market expects Progyny (PGNY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on A ...

Group 1 - Medpace Holdings, Inc. (MEDP) has reached an important support level and is considered a good stock pick from a technical perspective due to a recent "golden cross" event [1] - A golden cross is a bullish technical chart pattern formed when a short-term moving average, such as the 50-day, crosses above a longer-term moving average like the 200-day, indicating potential for a bullish breakout [2] - The golden cross pattern consists of three stages: a downtrend followed by a crossover of moving averages, and finally an upward price movement [3] Group 2 - MEDP shares have increased by 34.3% over the past four weeks, and the company holds a 1 (Strong Buy) rating on the Zacks Rank, suggesting a potential breakout [4] - The positive earnings outlook for MEDP is supported by five upward revisions in earnings estimates over the past 60 days, with no downward revisions, leading to an increase in the Zacks Consensus Estimate [4] - Investors are encouraged to monitor MEDP for further gains due to its key technical level and favorable earnings estimate revisions [5]

类似的纠纷在此前也有发生，比如北京迟某某就因质疑爱康国宾检测效果提起了诉讼。 据北京市丰台区人民法院判决书，法院查明：迟某某在2019年6月体检时已发现肝脏处有血管瘤，而 2020年10月爱康国宾公司为其体检时未发现血管瘤，迟某某为此又到北京大学人民医院进行B超检查， 结果为"肝脏多发占位，考虑血管瘤"。迟某某还诉称，他本人连续10年于爱康国宾进行体检，曾于2012 年因西直门分院未能检查出"肝血管瘤"而向爱康国宾提出过交涉。时隔8年后，爱康国宾再次出现同样 事故，同样的事项在同一人身上发生两次。法院认为爱康国宾公司在2020年10月的B超检查时不够仔 细，未尽到相应的注意义务，履行合同时存在瑕疵，导致迟某某另行支付了检查费用，迟某某主张的 500元支付检查费用获法院支持，他主张被告爱康国宾公司重新履行查体义务和公开赔礼道歉的诉请不 予支持。 宁夏市中级人民法院披露了一则判例，爱康国宾方面被判向原告共计支付10万元。 该案中，原告王女士分别于2012年12月22日、2014年3月5日在爱康国宾进行了全面健康体检，2次体检 结束后的《健康体检报告》均显示"宫颈液基薄层细胞学检测(TCT)：未见上皮内病变或癌变( ...

Core Viewpoint - WuXi AppTec reported strong financial performance in the first half of the year, with significant revenue and profit growth, driven by robust demand in its core business segments and strategic operational improvements [3][4][5]. Financial Performance - The company achieved operating revenue of 20.799 billion yuan, a year-on-year increase of 20.64% [3]. - Net profit attributable to shareholders reached 8.561 billion yuan, up 101.92% year-on-year [3]. - The net profit excluding non-recurring items was 5.582 billion yuan, reflecting a growth of 26.47% [3]. Quarterly Highlights - In Q2, WuXi AppTec's revenue surpassed 11.145 billion yuan for the first time, marking a historical milestone [4]. - The net profit for Q2 was 4.889 billion yuan, also a record for the same period [4]. - The company anticipates continued strong performance in Q3 and Q4, with quarterly revenues expected to remain above 10 billion yuan [4]. Business Segments - The chemical business remains the cornerstone of WuXi AppTec's revenue, accounting for nearly 80% of total income, with revenue of 16.301 billion yuan, a year-on-year increase of 33.51% [5]. - The small molecule process development and manufacturing (D&M) segment generated 8.68 billion yuan, growing 17.5% year-on-year [5]. Order Backlog - As of June 30, 2025, the company had a backlog of orders amounting to 56.69 billion yuan, a 37.2% increase year-on-year [5]. Profit Growth Drivers - Profit growth was attributed to a focus on the CRDMO business model, operational efficiency improvements, and increased capacity from late-stage clinical and commercialization projects [6]. - The sale of shares in WuXi XDC Cayman Inc. contributed significantly to profit, with investment income reaching 3.669 billion yuan, a 163-fold increase year-on-year [8]. Cash Flow and Dividends - The net cash flow from operating activities was 7.431 billion yuan, up 49.63% year-on-year [8]. - The board approved the company's first interim dividend, proposing a cash dividend of 3.5 yuan per 10 shares, totaling approximately 1 billion yuan [10]. - The company has completed cash dividends totaling 3.84 billion yuan in the first half of the year and is executing a share buyback plan valued at 1 billion yuan [12].

格隆汇7月31日丨三博脑科(301293.SZ)于投资者互动平台表示，公司部分院区部分科室有运用到AI智能 化产品和技术，一定程度上可以提高医疗服务质量和效率，但对公司业绩不会产生重大影响。 ...

CVS Health (CVS) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.83 per share a year ago. These figures are adjusted for non- recurring items. CVS Health shares have added about 38.8% since the beginning of the year versus the S&P 500's gain of 8.2%. What's Next for CVS Health? While CVS Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? O ...

济民健康（SH 603222，收盘价：6.92元）7月31日晚间发布公告称，截至2025年7月31日，公司通过集 中竞价交易方式累计回购股份约201万股，占公司总股本的比例为0.3819%，购买的最高价为6.13元/ 股，最低价为5.87元/股，已支付的总金额约为1209万元。 2024年1至12月份，济民健康的营业收入构成为：医药制造行业占比55.95%，医疗服务行业占比 41.43%，医药贸易行业占比1.75%，其他业务占比0.87%。 （文章来源：每日经济新闻） ...